Atypical expression and distribution of embryonic stem cell marker, OCT4, in human lung adenocarcinoma

Journal of Surgical Oncology

Volumn 102, Issue 6, 2010, Pages 689-698

  Karoubi, Golnaz ^a   Cortes Dericks, Lourdes ^a   Gugger, Mathias ^a   Galetta, Domenico ^b   Spaggiari, Lorenzo ^b   Schmid, Ralph A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

adenocarcinoma; cancer stem cells; lung cancer; OCT4A; OCT4B

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4A; OCTAMER TRANSCRIPTION FACTOR 4B; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELLS, CULTURED; HUMANS; LUNG; LUNG NEOPLASMS; OCTAMER TRANSCRIPTION FACTOR-3; PROTEIN ISOFORMS;

EID: 78349291802     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21665     Document Type: Article

References (51)

1. van Klaveren RJ, van't Westeinde SC, de Hoop BJ, et al.: Stem cells and the natural history of lung cancer: Implications for lung cancer screening. Clin Cancer Res 2009; 15: 2215-2218.
2. Shiau MC, Bonavita J, Naidich DP:, Adenocarcinoma of the lung: Current concepts in radiologic diagnosis and management. Curr Opin Pulm Med 2007; 13: 261-266.
3. Wang JC, Dick JE:, Cancer stem cells: Lessons from leukemia. Trends Cell Biol 2005; 15: 494-501. (Pubitemid 41253469)
4. Visvader JE, Lindeman GJ:, Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
5. Reya T, Morrison SJ, Clarke MF, et al.: Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
6. Carney DN, Gazdar AF, Bunn PA, Jr., et al.: Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. Stem Cells 1982; 1: 149-164.
7. Chen YC, Hsu HS, Chen YW, et al.: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 2008; 3: e2637.
8. Kim CF, Jackson EL, Woolfenden AE, et al.: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823-835.
9. Rapp UR, Ceteci F, Schreck R:, Oncogene-induced plasticity and cancer stem cells. Cell Cycle 2008; 7: 45-51.
10. Saigusa S, Tanaka K, Toiyama Y, et al.: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009; 16: 3488-3498.
11. Wang Q, He W, Lu C, et al.: Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res 2009; 29: 1233-1241.
12. Bass AJ, Watanabe H, Mermel CH, et al.: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41: 1238-1242.
13. Sotomayor P, Godoy A, Smith GJ, et al.: Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 2009; 69: 401-410.
14. Schoenhals M, Kassambara A, De Vos J, et al.: Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 2009; 383: 157-162.
15. Mizrak SC, Chikhovskaya JV, Sadri-Ardekani H, et al.: Embryonic stem cell-like cells derived from adult human testis. Hum Reprod 2009; 25: 158-167.
16. Scholer HR, Dressler GR, Balling R, et al.: Oct-4: A germline-specific transcription factor mapping to the mouse t-complex. EMBO J 1990; 9: 2185-2195.
17. Scholer HR, Ruppert S, Suzuki N, et al.: New type of POU domain in germ line-specific protein Oct-4. Nature 1990; 344: 435-439.
18. Pesce M, Wang X, Wolgemuth DJ, et al.: Differential expression of the Oct-4 transcription factor during mouse germ cell differentiation. Mech Dev 1998; 71: 89-98.
19. Liedtke S, Enczmann J, Waclawczyk S, et al.: Oct4 and its pseudogenes confuse stem cell research. Cell Stem Cell 2007; 1: 364-366.
20. Atlasi Y, Mowla SJ, Ziaee SA, et al.: OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. Stem Cells 2008; 26: 3068-3074.
21. Takeda S, North DL, Lakich MM, et al.: Evolutionarily conserved promoter motifs and enhancer organization in the mouse gene encoding the IIB myosin heavy chain isoform expressed in adult fast skeletal muscle. C R Acad Sci III 1992; 315: 467-472.
22. Lee J, Kim HK, Rho JY, et al.: The human OCT-4 isoforms differ in their ability to confer self-renewal. J Biol Chem 2006; 281: 33554-33565.
23. de Jong J, Looijenga LH:, Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: History and future. Crit Rev Oncog 2006; 12: 171-203.
24. Cauffman G, Liebaers I, Van Steirteghem A, et al.: POU5F1 isoforms show different expression patterns in human embryonic stem cells and preimplantation embryos. Stem Cells 2006; 24: 2685-2691.
25. Wang X, Zhao Y, Xiao Z, et al.: Alternative translation of OCT4 by an internal ribosome entry site and its novel function in stress response. Stem Cells 2009; 27: 1265-1275.
26. Papamichos SI, Lambropoulos AF, Kotoula V:, OCT4B expression in PBMNCs suggests the existence of an alternative OCT4 promoter. Genes Chromosomes Cancer 2009; 48: 1112-1114.
27. Papamichos SI, Kotoula V, Tarlatzis BC, et al.: OCT4B1 isoform: The novel OCT4 alternative spliced variant as a putative marker of stemness. Mol Hum Reprod 2009; 15: 269-270.
28. Monsef N, Soller M, Isaksson M, et al.: The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia. Prostate 2009; 69: 909-916.
29. Looijenga LH, Stoop H, de Leeuw HP, et al.: POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003; 63: 2244-2250.
30. Chen Z, Xu WR, Qian H, et al.: Oct4, a novel marker for human gastric cancer. J Surg Oncol 2009; 99: 414-419.
31. Cheng L, Sung MT, Cossu-Rocca P, et al.: OCT4: Biological functions and clinical applications as a marker of germ cell neoplasia. J Pathol 2007; 211: 1-9.
32. Atlasi Y, Mowla SJ, Ziaee SA, et al.: OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 2007; 120: 1598-1602.
33. Du Z, Jia D, Liu S, et al.: Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia 2009; 57: 724-733.
34. Tai MH, Chang CC, Kiupel M, et al.: Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005; 26: 495-502.
35. Cantz T, Key G, Bleidissel M, et al.: Absence of OCT4 expression in somatic tumor cell lines. Stem Cells 2008; 26: 692-697.
36. Kotoula V, Papamichos SI, Lambropoulos AF:, Revisiting OCT4 expression in peripheral blood mononuclear cells. Stem Cells 2008; 26: 290-291.
37. Liedtke S, Stephan M, Kogler G:, Oct4 expression revisited: Potential pitfalls for data misinterpretation in stem cell research. Biol Chem 2008; 389: 845-850.
38. Suo G, Han J, Wang X, et al.: Oct4 pseudogenes are transcribed in cancers. Biochem Biophys Res Commun 2005; 337: 1047-1051.
39. Drummond DA, Wilke CO:, The evolutionary consequences of erroneous protein synthesis. Nat Rev Genet 2009; 10: 715-724.
40. Lengner CJ, Welstead GG, Jaenisch R:, The pluripotency regulator Oct4: A role in somatic stem cells ? Cell Cycle 2008; 7: 725-728.
41. Trosko JE:, From adult stem cells to cancer stem cells: Oct-4 Gene, cell-cell communication, and hormones during tumor promotion. Ann NY Acad Sci 2006; 1089: 36-58.
42. Lengner CJ, Camargo FD, Hochedlinger K, et al.: Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell 2007; 1: 403-415.
43. Pochampally R:, Colony forming unit assays for MSCs. Methods Mol Biol 2008; 449: 83-91.
44. Zangrossi S, Marabese M, Broggini M, et al.: Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells 2007; 25: 1675-1680.
45. Pan GJ, Chang ZY, Scholer HR, et al.: Stem cell pluripotency and transcription factor Oct4. Cell Res 2002; 12: 321-329.
46. Gidekel S, Pizov G, Bergman Y, et al.: Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003; 4: 361-370.
47. Hochedlinger K, Yamada Y, Beard C, et al.: Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005; 121: 465-477.
48. Cheng CJ, Wu YC, Shu JA, et al.: Aberrant expression and distribution of the OCT-4 transcription factor in seminomas. J Biomed Sci 2007; 14: 797-807.
49. Wei F, Scholer HR, Atchison ML:, Sumoylation of Oct4 enhances its stability, DNA binding, and transactivation. J Biol Chem 2007; 282: 21551-21560.
50. Yasuhara N, Shibazaki N, Tanaka S, et al.: Triggering neural differentiation of ES cells by subtype switching of importin-alpha. Nat Cell Biol 2007; 9: 72-79.
51. Pan G, Qin B, Liu N, et al.: Identification of a nuclear localization signal in OCT4 and generation of a dominant negative mutant by its ablation. J Biol Chem 2004; 279: 37013-37020.